|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.12/-0.60
|
企業價值
50.21M
|
資產負債 |
每股賬面淨值
-0.84
|
現金流量 |
現金流量率
--
|
損益表 |
收益
2.43M
|
每股收益
0.01
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/01/21 18:50 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. |